NCT02737124

Brief Summary

Patients that are to undergo isolated meniscectomy will be randomized to 2 cohorts: one will take the FDA recommended dose of acetominophen (1000mg) 24hrs before surgery, one will be given a similarly looking placebo pill. A multitude of post-op variables will be included, mainly pain scores and morphine equivalent doses at different time points.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2017

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 8, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 13, 2016

Completed
10 months until next milestone

Study Start

First participant enrolled

February 16, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2018

Completed
18 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 19, 2018

Completed
Last Updated

July 26, 2018

Status Verified

July 1, 2018

Enrollment Period

1 year

First QC Date

April 8, 2016

Last Update Submit

July 23, 2018

Conditions

Keywords

AcetaminophenSurgeryMeniscectomy

Outcome Measures

Primary Outcomes (5)

  • Morphine-equivalent dose consumption

    Total morphine-equivalent dose consumption during immediate post-op, phase 1 recover, phase II recovery, at 2 days, and at 7 days

    7 days

  • Pain using the visual analogue scale

    The visual analogue scale is a scale with a line from 0 on one side and 100 on the other where the patient is asked to mark where they believe their pain is.

    7 Days

  • Narcotic Use

    Total morphine-equivalent dose consumption during immediate post-op, phase 1 recover, phase II recovery, at 2 days, and at 7 days will also be recorded.

    7 Days

  • Measure of time to discharge from the PACU

    Time to discharge from the PACU

    7 Days

  • Measure of time to discharge from hospital

    Time to discharge from the hospital

    7 Days

Study Arms (2)

1000 Mg Acetaminophen

EXPERIMENTAL

Acetaminophen will be given 24 hours before surgery

Drug: Acetaminophen

Placebo

ACTIVE COMPARATOR

A sugar pill will be given 24 hours before the scheduled surgery.

Other: Placebo

Interventions

Acetaminophen will be given 24 hours before scheduled surgery.

1000 Mg Acetaminophen
PlaceboOTHER

Placebo will be given to subjects 24 hours before scheduled surgery.

Also known as: Sugar Pill
Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must be at least 18 years of age
  • ASA Class I-II
  • Patients scheduled for meniscectomy

You may not qualify if:

  • Contraindication to acetaminophen (hypersensitivity, extensive alcohol history, liver disease, actively breastfeeding)
  • Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
  • Younger than 18 years of age or older than 65
  • Any patient considered a vulnerable subject
  • Patients on pain medication prior to surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University Medical Center

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

AcetaminophenSugars

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCarbohydrates

Study Officials

  • Eric Strauss, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 8, 2016

First Posted

April 13, 2016

Study Start

February 16, 2017

Primary Completion

March 1, 2018

Study Completion

March 19, 2018

Last Updated

July 26, 2018

Record last verified: 2018-07

Locations